Anti-PD-1 monoclonal antibody is named as a drug or biological intervention in 8 clinical trials in our China, USA and UK trial registers, 8 of which are recruiting. Lead sponsors include Corbus Pharmaceuticals Inc. (1), LigaChem Biosciences, Inc. (1) and Georgiamune Inc (1). Registered phases: Phase 1/2 and Phase 2. Conditions studied include Solid Tumor; Advanced Solid Tumors; Melanoma Stage IV.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Solid Tumor | 2 |
| Advanced Solid Tumors | 1 |
| Melanoma Stage IV | 1 |
| Locally Advanced or Metastatic Solid Tumors | 1 |
| Renal Cell Carcinoma | 1 |
| Radiotherapy | 1 |
| Immune Checkpoint Inhibitor | 1 |
| Pancreatic Cancer | 1 |
| Pancreatic Neoplasms | 1 |
| Pancreatic Ductal Adenocarcinoma | 1 |
| Advanced Cancer | 1 |
| Colorectal Cancer | 1 |
| Head and Neck Squamous Cell Carcinoma | 1 |
| Lead sponsor | Trials |
|---|---|
| Corbus Pharmaceuticals Inc. | 1 |
| LigaChem Biosciences, Inc. | 1 |
| Georgiamune Inc | 1 |
| Chinese PLA General Hospital | 1 |
| Jinling Hospital, China | 1 |
| Changhai Hospital | 1 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| Register | Anti-PD-1 monoclonal antibody trials |
|---|---|
| Clinical trials in China | 5 |
| Clinical trials in USA | 3 |
| Clinical trials in UK | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records โ it is not written from memory, and nothing here describes how Anti-PD-1 monoclonal antibody works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Anti-PD-1 monoclonal antibody (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.